PCN27 Analysis of Prevalence and Treatment of Multiple Myeloma in German Statutory Sick Funds Claim Data

Jörg Tomeczkowski(Janssen (Germany)), Wolfgang Knauf(Krankenhaus Bethanien), Daniel Wirth(Janssen (Germany)), Christoph Tapprich(Johnson & Johnson (Germany))

Value in Health

October 29, 2012

10.1016/j.jval.2012.08.1220

Cited by 0

Related Papers

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper

|Oncology Research and Treatment|2020|88

Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings

|Bone Marrow Transplantation|2005|81

Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes

|Experimental Hematology|2008|58

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

|Blood|2008|37

Burden of illness of follicular lymphoma and marginal zone lymphoma

|Annals of Hematology|2018|32